|
Patent landscape, scope, and claims: |
Executive summary
US Drug Patent 12,102,619 claims a tightly defined, therapeutic drug-management method for starting everolimus in Tuberous Sclerosis Complex (TSC) patients who have seizures while they are on cannabidiol (CBD). The core scope is (i) co-administration of CBD (synthetic or purified), (ii) a reduced everolimus start dose in a narrow mg/m² window, and (iii) therapeutic drug monitoring (TDM) with dose escalation after 1–2 weeks to reach specific everolimus PK exposure targets (trough, Cmax, and/or AUC0-24). Claims cascade into specific seizure syndromes and CBD dosing/purity and everolimus dose sub-ranges. The landscape risk for generic/biosimilar entry is concentrated in method-of-treatment enforcement via Orange Book-listed brand drugs that already pair with everolimus PK goals and TSC seizure indications, plus any pending Paragraph IV litigation where a challenger must avoid infringing these monitoring and dose-escalation parameters.
What does US Patent 12,102,619 claim about co-administering cannabidiol with everolimus for TSC seizures?
US 12,102,619 is a method of initiating everolimus treatment under a CBD background regimen in humans with TSC and seizures. The claim structure is a process claim with explicit clinical steps and PK-based criteria.
Claim 1: The protected initiation protocol (method scope)
Independent claim 1 requires all of the following in combination:
-
Patient condition
- Human suffering from TSC and has seizures.
- Currently receiving a “therapeutically effective amount of cannabidiol.”
-
Step (a): Co-administration with reduced everolimus start dose
- Co-administer everolimus at a reduced starting dose plus the therapeutically effective amount of cannabidiol.
- Everolimus reduced starting dose: about 2.25 mg/m² to about 4.5 mg/m² once daily.
-
Step (b): Everolimus blood level monitoring
- Monitor blood plasma concentration of everolimus.
- Monitoring timing: one to two weeks after the human begins receiving everolimus.
-
Step (c): Dose escalation to meet PK exposure targets
- Increase everolimus dose to achieve at least one of these exposure constraints:
- Trough 5–15 ng/mL, OR
- Cmax ≤ 50 ng/mL, OR
- AUC0-24 ≤ 500 h·ng/mL.
-
CBD identity constraint
- CBD is synthetic or purified.
Dependent claims 2–24: Scope narrowing by dosing, purity, hepatic impairment, and indications
The dependent claims narrow the independent method into sub-populations and additional parameter constraints.
CBD dosing and handling
- Claim 2: CBD dose ~5 to ~25 mg/kg/day.
- Claim 3: CBD specifically 25 mg/kg/day.
- Claim 7: CBD is purified.
- Claims 8–9: CBD purity:
- ≥95% w/w (claim 8)
- ≥98% w/w (claim 9)
Hepatic impairment stratification (everolimus start logic conditioned on liver status)
- Claim 4 (normal hepatic or mild impairment): CBD ~25 mg/kg/day with everolimus start dose as per claim 1 (not expressly re-parameterized in claim 4 beyond CBD amount).
- Claim 5 (moderate hepatic impairment): CBD ~12.5 mg/kg/day (and still uses the claim 1 method framework).
- Claim 6 (severe hepatic impairment): CBD ~5 mg/kg/day.
Everolimus start-dose sub-ranges and alternative dosing rhythm
- Claim 10: everolimus start dose range ~2.5 to ~4.5 mg/m² once daily.
- Claim 11: everolimus start dose specifically ~2.5 mg/m² once daily.
- Claim 13: everolimus start dose range ~2.25 to ~4.1 mg/m² once daily.
- Claim 14: everolimus start dose specifically ~2.25 mg/m² once daily.
- Claim 24: everolimus start at 4.5 mg/m² once daily every other day (rhythm constraint that may be treated as an additional limitation on the “once daily” framework in claim 1).
Indication-specific embodiments (TSC disease manifestations and seizure types)
- Claim 12: everolimus to treat TSC-associated partial onset seizures.
- Claims 15–16: everolimus to treat TSC-associated:
- subependymal giant cell astrocytoma (SEGA) (claim 15)
- renal angiomyolipoma (claim 16)
Seizure phenotype embodiments:
-
Claim 17: treating generalized seizures.
-
Claim 18: generalized seizures are tonic-clonic, tonic, clonic, or atonic.
-
Claim 19: treating focal seizures.
-
Claim 20: focal seizure definitions include motor without impairment, impaired awareness, and focal evolving to bilateral convulsive/generalized convulsive seizures.
-
Claims 21–22: seizure reduction endpoint relative to baseline:
- total seizures reduced compared to pre-CBD baseline (claim 21)
- reduction of at least 50% (claim 22)
-
Claim 23: explicitly restates that step (c) achieves trough 5–15 ng/mL (a narrower recitation of claim 1’s exposure language).
Built-in claim interpretation pressure points (where infringement risk concentrates)
- “All-elements” requirement: infringement requires the entire initiation + monitoring + PK target escalation sequence with the specified everolimus start dose window and CBD identity.
- Timing constraint: monitoring occurs one to two weeks after starting everolimus. Protocol deviations to earlier/later monitoring may avoid literal infringement.
- Dose target tripwire: step (c) uses PK thresholds that may be met by different dosing strategies. If a clinician escalates without reaching the claimed trough/Cmax/AUC thresholds, literal infringement weakens.
- CBD identity: “synthetic or purified” could be argued depending on formulation sourcing; however the claims also cover “purified” explicitly, and purity thresholds (≥95%, ≥98%) further narrow dependent claims.
How is the scope of US 12,102,619 likely evaluated: literal infringement vs. design-around?
Literal infringement would require a defendant’s method to perform each limitation of claim 1 in combination. For practical enforcement, the claim most likely maps to a clinical protocol where clinicians follow a known CBD + everolimus initiation regimen with TDM at 1–2 weeks and dose adjustment to achieve low everolimus exposure.
Design-around pathways implied by the claim structure
-
Change the everolimus start dose outside the window
- Claim 1: about 2.25 to about 4.5 mg/m² once daily.
- If dosing starts meaningfully below 2.25 mg/m² or above 4.5 mg/m² (and “about” is argued narrowly by prosecution history or exemplars), literal infringement can be reduced.
-
Change monitoring timing
- Claim 1 requires monitoring 1–2 weeks after everolimus initiation.
- Monitoring at day 4 or week 3–4 shifts outside the literal window.
-
Change the exposure target strategy
- Claim 1: dose escalates to trough 5–15 ng/mL, or Cmax ≤ 50 ng/mL, or AUC0-24 ≤ 500 h·ng/mL.
- A regimen that achieves therapeutic effect without steering to those exact thresholds can be positioned outside literal scope, depending on measured values.
-
CBD sourcing/quality constraint management
- Claim 1: CBD is synthetic or purified.
- Dependent claims include purity floors. A formulation not meeting those purity thresholds could avoid the dependent claims but may still infringe claim 1 if “synthetic or purified” is satisfied.
-
Avoid co-administration during initiation
- The method is expressly “initiating everolimus” in a person “currently being treated” with CBD.
- If everolimus is initiated after CBD discontinuation or CBD is not “current,” literal infringement is harder.
What therapeutic and PK parameter ranges does the patent protect for everolimus escalation in CBD-treated TSC patients?
US 12,102,619 protects a PK-controlled downshift initiation and controlled escalation design, consistent with a drug-drug interaction mitigation approach (everolimus exposure constrained while CBD is present).
Protected everolimus PK endpoints (Step c)
- Trough concentration: 5–15 ng/mL
- Cmax: ≤ 50 ng/mL
- AUC0-24: ≤ 500 h·ng/mL
Protected blood sampling window
- Monitoring occurs 1–2 weeks after starting everolimus.
Protected everolimus starting dose range (Step a)
- Independent: ~2.25–~4.5 mg/m² once daily
- Narrow dependent variants:
- ~2.25–~4.1 mg/m² once daily
- ~2.5–~4.5 mg/m² once daily
- ~2.25 mg/m² once daily
- ~2.5 mg/m² once daily
- Every-other-day rhythm: 4.5 mg/m² every other day (claim 24)
CBD parameter ranges and purity
- CBD “therapeutically effective amount”: ~5–~25 mg/kg/day (claim 2)
- Specific dose: 25 mg/kg/day (claim 3)
- Hepatic impairment dosing anchoring:
- normal/mild: ~25 mg/kg/day (claim 4)
- moderate: ~12.5 mg/kg/day (claim 5)
- severe: ~5 mg/kg/day (claim 6)
- CBD purity constraints (dependent):
- ≥95% w/w (claim 8)
- ≥98% w/w (claim 9)
What seizure types and TSC indications are explicitly covered by the patent claims?
The claims mix seizure phenotype coverage with TSC disease manifestation claims.
Seizure categories (method variations)
- Generalized seizures including:
- tonic-clonic
- tonic
- clonic
- atonic (claim 18)
- Focal seizures including:
- focal motor without impaired awareness
- focal with impaired awareness
- focal evolving to bilateral generalized convulsive seizures
- focal evolving to generalized convulsive seizures (claim 20)
TSC disease manifestations for everolimus (alternate embodiments)
- TSC-associated partial onset seizures (claim 12)
- SEGA (claim 15)
- renal angiomyolipoma (claim 16)
Efficacy endpoint limitations
- Reduction in total seizure counts vs baseline (claim 21)
- ≥50% reduction relative to baseline (claim 22)
What does the patent landscape look like around US 12,102,619 for US everolimus products?
This question requires enumeration of Orange Book listings, listed patents, assignment history, prosecution family members, and related litigations tied to US 12,102,619. No such bibliographic data, docket references, or family/patentee information is provided in the input. Per operating constraints, a complete and accurate landscape cannot be constructed without those records.
How strong is US 12,102,619 against generic or competitor entry attempting to avoid CBD-evorlimus initiation protocols?
Strength drivers
- Process specificity: The claim requires a concrete clinical algorithm (start dose range, CBD co-administration, TDM timing, exposure targets).
- Objective PK limits: Trough/Cmax/AUC thresholds provide measurable infringement criteria.
- Multiple dependent anchors: hepatic impairment dosing, purity floors, and seizure subtype/endpoint constraints give multiple “sublines” for enforcement.
Weakness drivers (from a design-around lens)
- Narrow patient-state and protocol: If competitors can change initiation timing, monitoring timing, start dose, or exposure targets, literal infringement risk decreases.
- “At least one exposure metric” construction: Step (c) includes an OR structure across trough/Cmax/AUC. This can widen infringement if the protocol hits any one metric, but it can also allow a design-around if none are met.
Practical litigation posture
If enforced, the evidentiary focus is likely on:
- what CBD formulation and dosing was used (synthetic/purified; purity if dependent claims asserted),
- the everolimus dose administered at initiation (mg/m² window),
- when blood samples were taken for everolimus levels (1–2 weeks),
- what the measured PK values were after escalation (trough/Cmax/AUC0-24),
- and whether dosing was escalated specifically to achieve those thresholds.
Key Takeaways
- US 12,102,619 is a protocol patent: it protects initiating everolimus in TSC seizure patients who are already on CBD, using reduced everolimus starting doses plus TDM at 1–2 weeks and PK-targeted escalation.
- Claim 1 is the main enforcement anchor: it combines patient selection, CBD identity (synthetic or purified), everolimus start dosing (about 2.25–4.5 mg/m² once daily), monitoring timing, and specific everolimus exposure limits.
- Dependent claims narrow the method into CBD dosing (5–25 mg/kg/day, and 25/12.5/5 mg/kg/day by hepatic impairment), CBD purity (≥95% or ≥98% w/w), additional everolimus dose variants, seizure phenotype subtypes, and seizure-reduction endpoints.
- Design-around risk is protocol-driven: changing initiation dose, monitoring timing, CBD co-administration status, or the strategy for reaching (or avoiding) the specified PK thresholds can reduce literal infringement exposure.
FAQs
- Can a regimen that monitors everolimus at 3 weeks avoid infringement of US 12,102,619?
- Does US 12,102,619 require achieving all three PK metrics (trough, Cmax, and AUC0-24) or just one?
- How do dependent claims on CBD purity (≥95% and ≥98% w/w) affect infringement strategy?
- If everolimus is started at 4.6 mg/m² once daily while on CBD, does it fall outside the claimed “about 4.5 mg/m²” range?
- Are seizure endpoint limitations (≥50% reduction) required for all infringement theories or only for the dependent claims that recite them?
References
No source material was provided in the prompt for citation; therefore no APA reference list can be generated.
More… ↓
⤷ Start Trial
|
